FDA grants approval for anthrax treatment

The Food and Drug Administration has accepted a Biologics License Application (BLA) for review from Elusys Therapeutics Inc.'s potential treatment for anthrax, Anthim, the company announced Monday.

BLA acceptance allows the treatment to be provided to national stockpiles and to be available on the market should a case appear in the U.S. They were granted approval based on positive results in both animal models for efficacy and human volunteer tests that proved that the compound is safe.

"Anthim has been developed under two contracts with the Biological Advanced Research and Development Authority (BARDA), and we look forward to continuing to work with BARDA in the interest of our nation's security," Elusys Therapeutics'  President and CEO Elizabeth Posillico said.

Anthim is an antibody that has been in development to act as a preventive measure and treatment option for inhaled forms of the anthrax bacteria. According to the company, it is the sole treatment of its kind to be in the late stages of investigation into intravenous and intramuscular administration.

Anthrax is considered a Category A pathogen in terms of biological terrorism threats. Inhaled forms are highly lethal and were used as part of a mail-based attack that infected 22 people, including mail carriers, in 2001.

Organizations in this Story

Elusys Therapeutics

Want to get notified whenever we write about Elusys Therapeutics ?
Next time we write about Elusys Therapeutics, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.